RxDoctor Payments Data

Galina Makovoz, MD

General Practice · West Hollywood, CANPI 1558351833

Payments from drug & device makers

$2,114in general payments, 2019–2025

Across 98 payments — averaging $21.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$475
  • AstraZeneca$253
  • Novartis$187
  • Amarin Pharma, Inc.$122
  • Almatica Pharma LLC$121
  • Lilly USA, LLC$117
  • plus $839 from 16 others

What the payments were for

  • Food & beverage$2,114100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,114 in reported general payments places this provider in the 90th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$168,929
Medicare patients
476
Services billed
2,322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide282$262,798
JanumetSitagliptin Phos/Metformin Hcl397$240,092
CreonLipase/Protease/Amylase360$217,468
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate251$213,225
LinzessLinaclotide373$207,463
JardianceEmpagliflozin242$165,003
Metformin Er GastricMetformin Hcl107$160,670
TrulicityDulaglutide148$151,039
MounjaroTirzepatide124$124,733
EliquisApixaban168$107,809
Diclofenac Sodium318$103,960
JanuviaSitagliptin Phosphate167$93,829
Diflorasone Diacetate170$91,817
Dexlansoprazole DrDexlansoprazole524$91,727
Lactulose68$80,434

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$66$424,931733 claims
MerckJanumet, Januvia$475$333,920564 claims
Novo NordiskOzempic, Rybelsus$84$285,517307 claims
Lilly USA, LLCTrulicity, Mounjaro$117$275,772272 claims
Boehringer IngelheimJardiance$30$165,003242 claims
PfizerEliquis$81$107,809168 claims
AstraZenecaFarxiga, Lokelma$253$76,387123 claims
Sumitomo Pharma America, Inc.Gemtesa$90$36,44153 claims
NovartisEntresto$187$23,35531 claims
GSKBreo Ellipta$16$20,84954 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 12,963 general practice providers in California.

Other general practice in West Hollywood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →